Emboline, Inc. Secures $20 Million in Growth Capital from Trinity Capital Inc. to Support Commercialization of the Emboliner® Embolic Protection System to Minimize Stroke Risk From TAVR
MWN-AI** Summary
Emboline, Inc., a Santa Cruz-based medical technology company, has successfully secured $20 million in growth capital from Trinity Capital Inc. This funding will support the commercialization of the Emboliner® Embolic Protection System, aimed at mitigating stroke risk associated with transcatheter aortic valve replacement (TAVR) procedures. The company is dedicated to reducing the incidence of stroke and ischemic complications during structural heart procedures.
The Emboliner® system is designed to provide comprehensive cerebral and systemic embolic protection by capturing and removing debris that may be released during these complex interventions. Emboline recently completed enrollment in its PROTECT H2H investigational device exemption (IDE) clinical trial, a pivotal study that assesses the effectiveness of its embolic protection technology.
The results of this IDE clinical trial will be showcased in a late-breaking session at the prestigious American College of Cardiology Annual Scientific Session on March 29, 2026, in New Orleans. This platform presents an opportunity for Emboline to share critical data with the medical community and outline the potential benefits of their technology.
Rob Lake, Senior Managing Director at Trinity Capital, expressed confidence in Emboline's technology, stating that it aims to provide cardiologists with the reassurance needed during critical structural heart procedures. Scott Russell, President and CEO of Emboline, highlighted that this financing positions the company favorably for its upcoming commercial launch in both the United States and Europe.
Overall, this significant funding will enable Emboline to advance its preparations for market entry while continuing to innovate its embolic protection technology, addressing the vital need for enhanced safety in cardiovascular procedures.
MWN-AI** Analysis
Emboline, Inc.'s recent acquisition of $20 million in growth capital from Trinity Capital is a significant stride in the commercialization of its Emboliner® Embolic Protection System, a technology designed to mitigate stroke risk during transcatheter aortic valve replacement (TAVR) procedures. As the company gears up for its commercial launch, several factors underscore the potential for investment and partnership opportunities within this promising medical technology sector.
Firstly, Emboline's technology addresses a crucial need in the cardiology field—a safe method to prevent embolic complications during structural heart interventions. With the completion of the PROTECT H2H investigational device exemption (IDE) clinical trial and forthcoming data presentation at the American College of Cardiology Annual Scientific Session, the momentum is building for positive clinical acceptance. Investors should monitor the outcomes of this trial closely, as favorable results could catalyze adoption among healthcare providers and pave the way for FDA approval.
Secondly, the strong backing from Trinity Capital not only validates Emboline's business model and product viability but also signals investor confidence in the future of embolic protection technologies. The strategic funding will support both market entry initiatives in the U.S. and Europe and ongoing innovation within Emboline’s product line. Companies with a robust intellectual property portfolio, as Emboline boasts, tend to have competitive advantages that can create sustainable growth opportunities.
In conclusion, Emboline represents an intriguing investment case, particularly for those focusing on the life sciences sector. Monitoring regulatory developments, clinical trial outcomes, and market penetration strategies will be essential for prospective investors. Given the increasing focus on advanced cardiac procedures and patient safety, Emboline's growth trajectory in mitigating stroke risks could yield compelling returns in the evolving healthcare landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
SANTA CRUZ, Calif., March 11, 2026 /PRNewswire/ -- Emboline, Inc., a privately held medical technology company focused on reducing stroke and ischemic damage during structural heart procedures such as transcatheter aortic valve replacement (TAVR), today announced it has closed $20 Million in growth capital from Trinity Capital, a leading international alternative asset manager.
Emboline recently completed enrollment in the PROTECT H2H investigational device exemption (IDE) clinical trial (NCT05684146), a prospective randomized study evaluating the Emboliner® Embolic Protection System. The funding will support Emboline's upcoming commercial launch activities and continued development of its embolic protection technology platform.
The Emboliner® Embolic Protection System is designed to provide full cerebral and systemic embolic protection by capturing and removing embolic debris released during transcatheter heart procedures. Emboline also holds an extensive intellectual property portfolio related to aortic embolic protection technologies, including full-body embolic filtration and aortic deflection approaches.
Results from the completed IDE clinical study will be presented in a Late-Breaking Clinical Trial session on March 29, 2026, at the American College of Cardiology Annual Scientific Session in New Orleans, Louisiana.
"Emboline's embolic filtering technology is designed with the goal of giving interventional cardiologists greater confidence when performing complex structural heart procedures while helping reduce the risk of stroke and other embolic complications," said Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital. "We are pleased to support Emboline during this important stage as the company prepares to bring its technology to physicians and patients worldwide."
"We are excited to partner with Trinity Capital at a pivotal moment for Emboline," said Scott Russell, President and CEO of Emboline. "With the completion of our IDE clinical trial and regulatory submissions ahead, this financing positions us to prepare for commercial launch in the United States and Europe later this year. Our goal is to provide physicians with a comprehensive embolic protection solution that helps reduce stroke and ischemic injury during transcatheter procedures."
With this financing, Emboline will advance preparations for the commercial introduction of the Emboliner® Embolic Protection System while continuing development of additional technologies designed to reduce embolic risk during structural heart interventions.
About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than $5.5 billion across over 463 investments since inception in 2008 (as of December 31, 2025). Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located across the United States and Europe. For more information on Trinity Capital, please visit trinitycapital.com and stay connected to the latest activity via LinkedIn and X (@trincapital).
About Emboline
Emboline, Inc. is a privately held medical technology company based in Santa Cruz, California, focused on developing technologies designed to reduce embolic complications during transcatheter cardiovascular procedures.
The company's lead product, the Emboliner® Embolic Protection System, is designed to provide full cerebral and systemic embolic protection by capturing and removing debris that may be released during structural heart interventions and that could otherwise travel to the brain and other vital organs.
For more information, visit emboline.com.
The Emboliner® device is currently investigational and is not available for commercial sale.
Media Contact: media@emboline.com
SOURCE Emboline, Inc.
FAQ**
How will the $20 million growth capital from Trinity Capital Inc. (TRIN) specifically enhance the commercialization strategies for the Emboliner® Embolic Protection System?
What are the anticipated impacts of the Emboliner® system on patient outcomes during transcatheter aortic valve replacement (TAVR) procedures as Emboline collaborates with Trinity Capital Inc. (TRIN)?
Can you elaborate on the key findings expected from the IDE clinical trial results, which will be presented at the American College of Cardiology Annual Scientific Session, and how Trinity Capital Inc. (TRIN) fits into this context?
What additional innovations in embolic protection technology are being explored by Emboline, Inc. following its partnership with Trinity Capital Inc. (TRIN) for financing?
**MWN-AI FAQ is based on asking OpenAI questions about Trinity Capital Inc. (NASDAQ: TRIN).
NASDAQ: TRIN
TRIN Trading
-2.24% G/L:
$14.21 Last:
1,205,257 Volume:
$14.42 Open:
